Silexion Therapeutics (SLXN) Price & Analysis

Compare

170 Followers

SLXN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$7.82 - $1,777.95

Previous CloseN/A

Volume52.80K

Average Volume (3M)125.16K

Market Cap

$5.13M

Enterprise Value$4.75M

Total Cash (Recent Filing)$6.15M

Total Debt (Recent Filing)$3.48M

Price to Earnings (P/E)―

Beta0.07

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-19.98

Shares Outstanding579,493

10 Day Avg. Volume268,601

30 Day Avg. Volume125,163

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.93

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.28

Forecast

1Y Price Target

$75.00

Price Target Upside729.65% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical DataSilexion announced positive pre-clinical data finding SIL-204 demonstrated anti-tumor activity in additional cancers including colorectal and lung cancers harboring KRAS mutations.

Market OpportunityThe global treatment market for cancers with KRAS mutations is estimated at over $30 billion annually, highlighting a significant commercial opportunity.

Bears Say

Price TargetThe 12-month price target has been lowered to $5.00, from $9.00 due to the additional dilution from the recent capital raise and warrant exercises.

Stock PerformanceShares are trading down ~35% following the warrant exercises.

Silexion Therapeutics News

Silexion Therapeutics Corp trading resumes

09:41 EDT Silexion Therapeutics (SLXN) Corp trading resumes Published first on TheFly – the ultimate source for real-time,...

6d ago

SLXN

Silexion Therapeutics Corp trading halted, volatility trading pause

09:31 EDT Silexion Therapeutics (SLXN) Corp trading halted, volatility trading pause Published first on TheFly – the ultimate...

6d ago

SLXN

Silexion reports data showing up to 90% inhibition of cancer cell growth

Silexion Therapeutics (SLXN) announced new preclinical data revealing unprecedented inhibition rates of up to 97% in pancreatic cancer...

7d ago

SLXN

Silexion Therapeutics Corp trading resumes

10:10 EDT Silexion Therapeutics (SLXN) Corp trading resumes Published first on TheFly – the ultimate source for real-time,...

7d ago

SLXN

Silexion Therapeutics Corp trading halted, volatility trading pause

09:55 EDT Silexion Therapeutics (SLXN) Corp trading halted, volatility trading pause Published first on TheFly – the ultimate...

7d ago

SLXN

Silexion Therapeutics Corp trading halted, news pending

19:50 EDT Silexion Therapeutics (SLXN) Corp trading halted, news pending Published first on TheFly – the ultimate source...

10d ago

SLXN

Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested

These are the upcoming stock splits for the week of July 28 to August 1, based on TipRanks’ Stock...

12d ago

AGRI

AIHS

Silexion Therapeutics announces 1-for-15 reverse share split

Silexion Therapeutics (SLXN) announced a 1-for-15 reverse share split of its ordinary shares. The reverse share split will...

23d ago

SLXN

Silexion Therapeutics announces results from preclinical study of SIL204

Silexion Therapeutics (SLXN) announced new positive preclinical data demonstrating SIL204’s significant efficacy in human lung cancer cell lines....

30d ago

SLXN

Buy Rating for Silexion Therapeutics Driven by Promising Preclinical Data and Financial Strength

Maxim Group analyst Naz Rahman reiterated a Buy rating on Silexion Therapeutics yesterday and set a price target...

5d ago

SLXN

Silexion Therapeutics Enters Inducement Offer Agreement

Silexion Therapeutics ( ($SLXN) ) just unveiled an announcement. On July 31, 2025, Silexion Therapeutics entered into an...

6d ago

SLXN

Silexion Therapeutics Reveals Promising Preclinical Data for SIL204

The latest announcement is out from Silexion Therapeutics ( ($SLXN) ). On July 31, 2025, Silexion Therapeutics announced...

7d ago

SLXN

Silexion Therapeutics Completes Reverse Share Split

The latest announcement is out from Silexion Therapeutics ( ($SLXN) ). Silexion Therapeutics announced the completion of a...

9d ago

SLXN

Silexion Plans Reverse Split to Regain Nasdaq Compliance

Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On July 18, 2025, Silexion Therapeutics received a notification...

17d ago

SLXN

SLXN FAQ

What was Silexion Therapeutics Corp’s price range in the past 12 months?

Silexion Therapeutics Corp lowest stock price was $7.82 and its highest was $1777.95 in the past 12 months.

What is Silexion Therapeutics Corp’s market cap?

Silexion Therapeutics Corp’s market cap is $5.13M.

When is Silexion Therapeutics Corp’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Silexion Therapeutics Corp’s earnings last quarter?

Silexion Therapeutics Corp released its earnings results on Mar 18, 2025. The company reported -$11.55 earnings per share for the quarter, beating the consensus estimate of -$14.7 by $3.15.

Is Silexion Therapeutics Corp overvalued?

According to Wall Street analysts Silexion Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Silexion Therapeutics Corp pay dividends?

Silexion Therapeutics Corp does not currently pay dividends.

What is Silexion Therapeutics Corp’s EPS estimate?

Silexion Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Silexion Therapeutics Corp have?

Silexion Therapeutics Corp has 579,493 shares outstanding.

What happened to Silexion Therapeutics Corp’s price movement after its last earnings report?

Silexion Therapeutics Corp reported an EPS of -$11.55 in its last earnings report, beating expectations of -$14.7. Following the earnings report the stock price went down -0.962%.

Which hedge fund is a major shareholder of Silexion Therapeutics Corp?

Currently, no hedge funds are holding shares in SLXN

Silexion Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-590.37%

Trailing 12-Months

Asset Growth

42.21%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Silexion Therapeutics Corp

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Silexion Therapeutics (SLXN) Earnings & Revenues

Historic Earnings Reports

SLXN Stock 12 Month Forecast

Average Price Target

$75.00

▲(729.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","401":"$401","794":"$794","1187":"$1,187","1580":"$1,580"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,401,794,1187,1580],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.28,14.335384615384616,19.39076923076923,24.446153846153848,29.50153846153846,34.55692307692308,39.612307692307695,44.667692307692306,49.723076923076924,54.77846153846154,59.83384615384615,64.88923076923076,69.94461538461539,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.28,14.335384615384616,19.39076923076923,24.446153846153848,29.50153846153846,34.55692307692308,39.612307692307695,44.667692307692306,49.723076923076924,54.77846153846154,59.83384615384615,64.88923076923076,69.94461538461539,{"y":75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.28,14.335384615384616,19.39076923076923,24.446153846153848,29.50153846153846,34.55692307692308,39.612307692307695,44.667692307692306,49.723076923076924,54.77846153846154,59.83384615384615,64.88923076923076,69.94461538461539,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1545.75,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1528.2,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1579.5,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":197.1,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":75.09,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.67,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.15,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >